|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| A61K 39/00 |
| (11) | Patento numeris | 3054976 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14853023.1 |
| Europos patento paraiškos padavimo data | 2014-10-10 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-08-17 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-07-08 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2014/060129 |
| Data | 2014-10-10 |
| (87) | Numeris | WO 2015/054628 |
| Data | 2015-04-16 |
| (30) | Numeris | Data | Šalis |
| 201361889421 P | 2013-10-10 | US |
| (72) |
ZAUDERER, Maurice, US
|
| (73) |
Vaccinex, Inc.,
1895 Mt. Hope Avenue, Rochester, NY 14620,
US
|
| (54) | USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATMENT OF ATHEROSCLEROSIS |
| USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATMENT OF ATHEROSCLEROSIS |